Psy18 - Rapid Improvements in Motor Function in Spinal Muscular Atrophy Type 1 Following Avxs-101 Gene Replacement Therapy

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2595
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy16 - Health Outcome Improvements in Spinal Muscular Atrophy Type 1 Patients With Avxs-101 Gene Replacement Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

014 AVXS-101 Gene-Replacement Therapy (GRT) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

P.065 AVXS-101 Gene-Replacement Therapy (GRT)) in Presymptomatic Spinal Muscular Atrophy (SMA): Study Update

Canadian Journal of Neurological Sciences
MedicineNeurology
2019English

066 Avxs-101 Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

Spinal Muscular Atrophy Type 1

Pediatric Critical Care Medicine
Child HealthCritical CarePediatricsPerinatologyIntensive Care Medicine
2012English

Gene Therapy in Mouse Models of Spinal Muscular Atrophy :||Using SMN Gene Replacement to Address Biological Questions

English

Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy

Neural Plasticity
Neurology
2017English

Respiratory Management of the Infant With Type 1 Spinal Muscular Atrophy

Archives of Disease in Childhood
Child HealthPediatricsPerinatology
2005English

Dysregulation of Synaptogenesis Genes Antecedes Motor Neuron Pathology in Spinal Muscular Atrophy

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy